EUVIMEDEUVIMED entdecken
Crossref

Combination therapy with levofloxacin and the probiotic Clostridium butyricum MIYAIRI 588 enhances immune checkpoint inhibitor efficacy

Kohei Tajima iD, Masahiro Hosonuma, Eiji Funayama, Junya Isobe, Yuta Baba, Masakazu Murayama, Yoichiro Narikawa, Hitoshi Toyoda, Toshiaki Tsurui, Yuki Maruyama, Aya Sasaki, Yasunobu Amari und 14 weitere

International Journal of Cancer · 2025-09 · 157 (5) · 993-1005

DOI: 10.1002/ijc.35472 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 06.06.2025. Verfasst von Kohei Tajima und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japa…. Hauptthemen laut MEDLINE: Levofloxacin, Clostridium butyricum, Immune Checkpoint Inhibitors, Probiotics. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The gut microbiome influences immune checkpoint inhibitor (ICI) efficacy. In this study, we explored the effects of combined levofloxacin (LVFX) and Clostridium butyricum MIYAIRI 588 (CBM588) on ICI outcomes using a CT26 tumor model in BALB/c mice. When compared with the control, the LVFX+CBM588 combination enhanced anti‐programmed cell death (PD)‐1 therapy, with CD8 + T cells playing a key role. Gut microbiota analysis showed reduced Lactobacillus relative abundance and increased Oscillibacter and Muribaculaceae in the LVFX+CBM588 group. A broad‐spectrum antibiotic cocktail (ampicillin, neomycin, vancomycin, and metronidazole) with CBM588 diminished antitumor effects and reduced survival in mice when compared with the control, demonstrating the importance of microbiota‐targeted therapeutic combinations. However, while LVFX+CBM588 improved ICI efficacy, it worsened dextran sulfate sodium (DSS)‐induced colitis, suggesting immune activation contributes to inflammation. These findings emphasize the potential of customized antibiotic–probiotic combinations in cancer immunotherapy, while also stressing the necessity to manage immune‐related adverse effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LevofloxacinClostridium butyricumImmune Checkpoint InhibitorsProbioticsAnimalsMiceMice, Inbred BALB CGastrointestinal MicrobiomeFemaleCell Line, TumorAnti-Bacterial AgentsCD8-Positive T-LymphocytesHumansColitis

Stichwörter der Autor:innen

clostridium butyricum MIYAIRI 588gut microbiomeimmune checkpoint inhibitorslevofloxacinprobiotics

Substanzen

LevofloxacinImmune Checkpoint InhibitorsAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan.
  • Department of Gastroenterological Surgery, Tokai University School of Medicine, Kanagawa, Japan.
  • Department of Pharmacology, Showa Medical University Graduate School of Medicine, Tokyo, Japan.
  • Pharmacological Research Center, Showa Medical University, Tokyo, Japan.
  • Division of Medical Oncology, Department of Medicine, Showa Medical University Graduate School of Medicine, Tokyo, Japan.
  • Department of Pharmacology, Showa Medical University Graduate School of Pharmacy, Tokyo, Japan.

ORCID-Profile: Kohei Tajima, Takuya Tsunoda

Zitieren

APA

Tajima, K., Hosonuma, M., Funayama, E., Isobe, J., Baba, Y., Murayama, M., Narikawa, Y., Toyoda, H., Tsurui, T., Maruyama, Y., Sasaki, A., Amari, Y., Yamazaki, Y., Nakashima, R., Shida, M., Sasaki, A., Sambe, T., Wada, S., Tsuji, M., …, & Yoshimura, K. (2025). Combination therapy with levofloxacin and the probiotic Clostridium butyricum MIYAIRI 588 enhances immune checkpoint inhibitor efficacy. International Journal of Cancer, 157(5), 993-1005. https://doi.org/10.1002/ijc.35472

Vancouver

Tajima K, Hosonuma M, Funayama E, Isobe J, Baba Y, Murayama M, et al. Combination therapy with levofloxacin and the probiotic Clostridium butyricum MIYAIRI 588 enhances immune checkpoint inhibitor efficacy. International Journal of Cancer. 2025;157(5):993-1005. doi:10.1002/ijc.35472

BibTeX
@article{Tajima2025,
  author = {Tajima, Kohei and Hosonuma, Masahiro and Funayama, Eiji and Isobe, Junya and Baba, Yuta and Murayama, Masakazu and Narikawa, Yoichiro and Toyoda, Hitoshi and Tsurui, Toshiaki and Maruyama, Yuki and Sasaki, Aya and Amari, Yasunobu and Yamazaki, Yoshitaka and Nakashima, Rie and Shida, Midori and Sasaki, Akiko and Sambe, Takehiko and Wada, Satoshi and Tsuji, Mayumi and Kiuchi, Yuji and Kobayashi, Shinichi and Kuramasu, Atsuo and Tsunoda, Takuya and Mori, Masaki and Koyanagi, Kazuo and Yoshimura, Kiyoshi},
  title = {Combination therapy with levofloxacin and the probiotic Clostridium butyricum MIYAIRI 588 enhances immune checkpoint inhibitor efficacy},
  journal = {International Journal of Cancer},
  year = {2025},
  volume = {157},
  number = {5},
  pages = {993--1005},
  doi = {10.1002/ijc.35472}
}
Kostenlos starten →